AstraZeneca Pharma India Ltd has surrendered the marketing authorisation for Olaparib (Lynparza) 100mg and 150mg for a specific prostate cancer treatment, which they never marketed since receiving the authorisation on November 17, 2023, due to commer
AI Assistant
Astrazeneca Pharma India Ltd
2025
Announcement
Find Answers
Ask about any part of the document to get insights, explanations, or key details.